NCT01940848 - Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

October 11, 2013

Primary Completion Date

October 25, 2017

Study Completion Date

October 25, 2017

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

STW5 (Iberogast, BAY98-7411)

Applied orally over 28 days, 20 drops STW 5 three times daily

DRUG

Placebo

Applied orally over 28 days, 20 drops placebo three times daily

Trial Locations (19)

12157

Berlin

13055

Berlin

14482

Potsdam

21423

Winsen

23858

Reinfeld

26203

Wardenburg

32584

Löhne

35457

Lollar

45355

Essen

45770

Marl

58095

Hagen

65185

Wiesbaden

67067

Ludwigshafen am Rhein

68165

Mannheim

71640

Ludwigsburg

76547

Sinzheim

99444

Blankenhain

99510

Apolda

06108

Halle